SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood (HOOD) is trending following a mixed earnings report that saw an EPS beat offset by a revenue miss, largely due to a decline in cryptocurrency trading. Community sentiment is polarized between concerns over valuation and crypto's impact, and optimism surrounding record annual performance, strong subscriber growth, new prediction markets, and a significant share buyback program.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is trending following mixed quarterly earningsan EPS beat, largely attributed to a one-time tax benefit, contrasted with a revenue miss and soft guidancewhich led to a significant sell-off despite a new $1 billion share buyback. Community discussion is sharply polarized between those buying the dip on growth and future autonomous vehicle potential, and others emphasizing persistent competitive pressures and the increasing perceived threat of robotaxis.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is trending after its robust Q4 earnings and strong revenue guidance, which has spurred community discussion on its increasing importance as a core infrastructure provider for the "agentic internet" and AI workloads. Sentiment is highly positive, with many viewing the company as a top beneficiary in the AI era.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is trending following its robust Q4 earnings report, which exceeded revenue and EPS expectations and included optimistic long-term growth targets and a planned CEO transition. While many investors are bullish on the AI lending platform's performance and potential for a short squeeze, the stock's tempered price reaction in a challenging fintech sector has fueled widespread market confusion and debate.

Astera Labs, Inc. is a global semiconductor company, which engages in the provision of hardware and software solutions for AI and cloud infrastructure applications to solve data, memory, and networking bottlenecks. It operates through the following geographical segments: Taiwan, China, United States, and Other. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs is trending as its recent Q4 earnings and Q1 guidance, while exceeding expectations, prompted a "sell the news" reaction, fueling community debate over its high valuation and characteristic volatility. Despite this, its integral role in AI infrastructure connectivity and a new warrant deal with Amazon tied to future purchases lead many to view the dip as a strategic buying opportunity.

Mattel, Inc. engages in the ownership of children's and family entertainment franchises. It operates through the following segments: North America, International, and American Girl. The North America and International segments focus on marketing and selling toys and consumer products. The American Girl segment includes marketing, retailing, and publishing dedicated to its mission to help girls grow up with confidence and character. The company was founded by Elliot Handler, Ruth Handler, and Harold Matson in 1945 and is headquartered in El Segundo, CA.

Mattel, Inc.

Mattel is experiencing a dramatic sell-off after missing Q4 earnings expectations and providing a weaker 2026 profit outlook, with the stock recently hitting a 52-week high before plummeting. The community is sharply divided, with many debating if the steep decline is an overreaction and looking to buy the dip, while others anticipate further downside.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending after reporting weaker recent earnings and significant losses in its electric vehicle division, but strong future profit guidance and a strategic pivot to hybrids are driving positive investor sentiment and a perceived "margin-rebuild" narrative. This has sparked mixed community reactions and ongoing discussion around broader auto sector challenges with EV profitability.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy is trending amid significant news regarding its role as the sole domestic producer of High-Assay Low-Enriched Uranium (HALEU), highlighted by a $900 million U.S. Department of Energy award and a National Nuclear Security Administration intent to sole-source enrichment. While many in the community are bullish on its long-term necessity for advanced nuclear reactors and AI power demand, concerns about potential shareholder dilution from a newly announced $1 billion at-the-market equity offering are fueling active discussion and recent volatility.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following its recent earnings report, which, despite showing strong revenue growth and significantly reduced cash burn, saw a "sell the news" reaction due to a larger-than-expected loss and a revised profitability timeline. The community is actively debating whether the sharp sell-off presents a buying opportunity, with bulls emphasizing improving fundamentals and bullish analyst coverage positioning Jumia as a key player in Africa's rapidly developing e-commerce market.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending due to groundbreaking five-year data from its personalized cancer vaccine trial with Merck, showcasing the potential of its mRNA platform in oncology; however, the stock faces significant volatility and community discussion following the FDA's refusal to review its influenza vaccine and ongoing patent litigation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has received an average rating of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat.com reports. One...

Rani Therapeutics (NASDAQ:RANI) Stock Price Down 2.2% - What's Next?

Rani Therapeutics (NASDAQ:RANI) Trading Down 2.2% - Time to Sell...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are covering the stock...

Rani Therapeutics (NASDAQ:RANI) Stock Price Up 1.3% - Here's Why

Rani Therapeutics (NASDAQ:RANI) Stock Price Up 1.3% - Here's Why...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock...

Investors Purchase High Volume of Put Options on Rani Therapeutics (NASDAQ:RANI)

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Stock investors acquired 12,455 put options on the stock. This...

Rani Therapeutics (NASDAQ:RANI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Rani Therapeutics (NASDAQ:RANI - Get Free Report) released its earnings results on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus...

Rani Therapeutics Holdings Inc. (RANI) on Friday announced that it has entered into a strategic collaboration with Chugai Pharmaceutical Co., aiming to advance the development of an oral therapeutic using its proprietary RaniPill technology.&nbsp;Chugai will work with Rani to create and commercialize a new oral product based on an experimental antibody for rare diseases. Under the deal, Rani will receive $10 million upfront.Beyond the upfront payment, Rani may earn up to $75 million in development-related milestones, another $100 million based on commercial achievements, and single-digit royalties on sales once the product reaches the market. The agreement grants Chugai an initial license for one drug target, with the possibility of expanding to five more. The total potential payments could reach $1.085 billion if all options are exercised.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/RANI">Rani Therapeutics' stock</a> traded over 165% higher in Friday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;By partnering with Chugai, the company gains access to a promising rare disease pipeline while reinforcing its financial position.&nbsp;&nbsp;“There are many cases where oral therapies for the treatment of multiple disease areas with high unmet medical needs, including rare and immunologic diseases, are limited and as a result, patients rely primarily on injections that can be burdensome and impact adherence,” said Rani CEO, Talat Imran.&nbsp;&nbsp;In a parallel move, Rani announced a private placement financing expected to generate about $60.3 million in gross proceeds.Rani Therapeutics’ stock has lost over 65% in 2025 and over 82% in the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stellantis-joins-hands-with-pony-ai-to-power-self-driving-vans-in-europe/ch6sdh6R3FD">Stellantis Stock Edges Up Premarket: Legacy Auto Giant Joins Hands With China's Pony AI To Power Self-Driving Vans In Europe</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Rani Therapeutics’ Stock Skyrocketing Pre-Market Today?

The total potential payments from the collaboration could reach $1.085 billion if all options are exercised.

Equity

The total potential payments from the collaboration could reach $1.085 billion if all options are exercised.


These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits followers in the week ended Feb. 7, 2025:GH Research PLC (+103% jump in followers)&nbsp;GH Research PLC focuses on developing mebufotenin-based therapies for treatment-resistant depression. The company’s inhalable candidate, GH001, met its primary endpoint in a Phase 2b trial, showing a significant reduction in depression scores compared to placebo. Secondary endpoints also showed improvements, with no serious adverse events reported.&nbsp;Despite the promising data, GHRS stock fell more than 28% over the past week.Lipella Pharmaceuticals Inc. (+40% jump in followers)Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus. The condition affects around 6 million Americans and currently has no FDA-approved therapies. The program allows patients with serious unmet medical needs to access the treatment outside of clinical trials.&nbsp;Following the announcement, LIPO stock climbed nearly 14% last week.MBX Biosciences Inc. (+39% jump in followers)MBX Biosciences, focused on peptide therapies for endocrine and metabolic disorders, had no major catalyst last week. However, in January, the company reported positive results from a Phase 1 trial of its long-acting GLP-1 receptor antagonist, MBX 1416, which showed a favorable safety profile.&nbsp;MBX shares surged more than 25% over the past week.Rani Therapeutics Holdings Inc. (+29% jump in followers)Rani Therapeutics, which is developing oral alternatives to injectable biologics, shared new preclinical data on its RaniPill capsule for delivering semaglutide. The study showed successful drug delivery with bioavailability and weight-loss effects comparable to subcutaneous administration. The company plans to start Phase 1 trials of a GLP-1/GLP-2 dual agonist in 2025.&nbsp;RANI stock rose over 12% last week.Invivyd Inc. (+21% jump in followers)Invivyd, which focuses on monoclonal antibodies for viral diseases, reported positive data from its ongoing Phase 1/2 trial of VYD2311, a potential alternative to COVID-19 vaccines. The candidate showed strong antiviral activity and a promising safety profile. The data, combined with results from its Phase 3 CANOPY trial, support its potential as a long-acting COVID-19 treatment.&nbsp;Invivyd shares soared over 355% last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Rani Therapeutics Holdings Inc - Ordinary Shares Class A

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $SHOP earnings on Wednesday?

RANI
Rani Therapeutics Holdings Inc - Ordinary Shares Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RANI News

RANIRani Therapeutics Holdings Inc - Ordinary Shares Class A